State Street
VTGN icon

State Street’s VistaGen Therapeutics VTGN Stock Holding History

State Street’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Hold
121,114
– – ﹤0.01% 4110
2026
Q1 		$69.2K Hold
121,114
– – ﹤0.01% 4085
2025
Q4 		$80.2K Buy
121,114
+24,256
+25% +$87.6K ﹤0.01% 4083
2025
Q3 		$344K Hold
96,858
– – ﹤0.01% 3747
2025
Q2 		$194K Hold
96,858
– – ﹤0.01% 3845
2025
Q1 		$242K Hold
96,858
– – ﹤0.01% 3779
2024
Q4 		$286K Buy
96,858
+8,150
+9% +$22.9K ﹤0.01% 3766
2024
Q3 		$267K Hold
88,708
– – ﹤0.01% 3756
2024
Q2 		$309K Buy
88,708
+5,000
+6% +$21.7K ﹤0.01% 3690
2024
Q1 		$442K Buy
83,708
+34,200
+69% +$164K ﹤0.01% 3678
2023
Q4 		$254K Buy
49,508
+24,044
+94% +$91K ﹤0.01% 3838
2023
Q3 		$133K Hold
25,464
– – ﹤0.01% 4040
2023
Q2 		$47.6K Sell
25,464
-188,937
-88% -$662K ﹤0.01% 4430
2023
Q1 		$802K Buy
214,401
+8,975
+4% +$47.1K ﹤0.01% 3600
2022
Q4 		$635K Buy
205,426
+17,690
+9% +$66.6K ﹤0.01% 3678
2022
Q3 		$857K Buy
187,736
+57,889
+45% +$574K ﹤0.01% 3627
2022
Q2 		$3.43M Buy
129,847
+9,519
+8% +$336K ﹤0.01% 3280
2022
Q1 		$4.48M Sell
120,328
-166,346
-58% -$7.25M ﹤0.01% 3236
2021
Q4 		$16.8M Buy
286,674
+24,836
+9% +$1.62M ﹤0.01% 2594
2021
Q3 		$21.5M Buy
261,838
+159,851
+157% +$13.9M ﹤0.01% 2433
2021
Q2 		$9.64M Buy
+101,987
New +$7.56M ﹤0.01% 2938

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

State Street's VTGN Position: Q2 2026 in Review

State Street held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 121,114 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4110.

State Street first reported a position in VTGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $21.5M in Q3 2021. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • State Street held 121,114 shares of VistaGen Therapeutics worth $27.4K as of Q2 2026.
  • State Street left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4110 holding.
  • State Street first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • State Street's VistaGen Therapeutics position peaked at $21.5M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.